Reduces serum phosphorus. ANDA 202315, held by Heritage Pharms Inc. Calcium Acetate.
As of Nov 16, 2026, ANDA 202315 (Calcium Acetate), held by Heritage Pharms Inc, was first approved by FDA on Jun 29, 2015, with 0 approved supplements and 0 published complete response letters.
Calcium acetate capsule is a phosphate binder indicated for the reduction of serum phosphorus in patients with end stage renal disease. Calcium acetate capsule is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (ESRD).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 29, 2015 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Calcium Acetate667MG · capsule;oral | Calcium Acetate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters